Significant Cross of Two Hundred Day Moving Average - ZBH
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 15 2025
0mins
Source: NASDAQ.COM
52 Week Range: ZBH's stock has a 52-week low of $89.24 and a high of $114.72, with the last trade recorded at $100.96.
Source of Information: The data regarding ZBH's stock performance was sourced from Technical Analysis Channel.com.
Analyst Views on ZBH
Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 100.47 USD with a low forecast of 88.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
4 Buy
11 Hold
3 Sell
Hold
Current: 87.540
Low
88.00
Averages
100.47
High
120.00
Current: 87.540
Low
88.00
Averages
100.47
High
120.00
About ZBH
Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
